[go: up one dir, main page]

FI943171A0 - Ureaasipohjainen rokote Helicobacter-infektiota vastaan - Google Patents

Ureaasipohjainen rokote Helicobacter-infektiota vastaan

Info

Publication number
FI943171A0
FI943171A0 FI943171A FI943171A FI943171A0 FI 943171 A0 FI943171 A0 FI 943171A0 FI 943171 A FI943171 A FI 943171A FI 943171 A FI943171 A FI 943171A FI 943171 A0 FI943171 A0 FI 943171A0
Authority
FI
Finland
Prior art keywords
urea
vaccine against
based vaccine
helicobacter infection
against helicobacter
Prior art date
Application number
FI943171A
Other languages
English (en)
Swedish (sv)
Other versions
FI943171L (fi
FI112032B (fi
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Iiaas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI943171(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of FI943171A0 publication Critical patent/FI943171A0/fi
Publication of FI943171L publication Critical patent/FI943171L/fi
Application granted granted Critical
Publication of FI112032B publication Critical patent/FI112032B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI943171A 1992-11-03 1994-07-01 Menetelmä ureaasipohjaisen rokotteen valmistamiseksi Helicobacter-infektiota vastaan FI112032B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US97099692 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection
US8593893 1993-07-06
PCT/EP1993/003059 WO1994009823A1 (en) 1992-11-03 1993-11-02 Urease-based vaccine against helicobacter infection
EP9303059 1993-11-02

Publications (3)

Publication Number Publication Date
FI943171A0 true FI943171A0 (fi) 1994-07-01
FI943171L FI943171L (fi) 1994-09-01
FI112032B FI112032B (fi) 2003-10-31

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943171A FI112032B (fi) 1992-11-03 1994-07-01 Menetelmä ureaasipohjaisen rokotteen valmistamiseksi Helicobacter-infektiota vastaan

Country Status (29)

Country Link
US (1) US5972336A (fi)
EP (2) EP1170016A3 (fi)
JP (1) JPH07503255A (fi)
KR (1) KR100287424B1 (fi)
CN (1) CN1111429C (fi)
AT (1) ATE217196T1 (fi)
AU (2) AU678195C (fi)
BR (1) BR9305711A (fi)
CA (1) CA2127283A1 (fi)
CZ (1) CZ284416B6 (fi)
DE (1) DE69331901T2 (fi)
DK (1) DK0625053T3 (fi)
ES (1) ES2176232T3 (fi)
FI (1) FI112032B (fi)
GE (1) GEP20012429B (fi)
HU (1) HU219760B (fi)
IL (1) IL107474A (fi)
MX (1) MX9306841A (fi)
NO (1) NO942490L (fi)
NZ (2) NZ258118A (fi)
OA (1) OA10087A (fi)
PL (1) PL174448B1 (fi)
PT (1) PT625053E (fi)
RO (1) RO114870B1 (fi)
RU (1) RU2125891C1 (fi)
SG (1) SG70978A1 (fi)
SK (1) SK280619B6 (fi)
WO (1) WO1994009823A1 (fi)
ZA (1) ZA938203B (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
ATE244578T1 (de) * 1993-07-27 2003-07-15 Csl Ltd Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
AUPM612494A0 (en) 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
EP0769018B1 (en) * 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteins and vaccines
AU723063B2 (en) * 1995-04-28 2000-08-17 Oravax, Inc Multimeric, recombinant urease vaccine
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
EP0840796A2 (en) * 1995-07-26 1998-05-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
WO1998049318A1 (fr) * 1997-04-30 1998-11-05 Pasteur Merieux Serums & Vaccins Composition vaccinale anti-helicobacter a base d'adn
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
AU770498B2 (en) 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
WO2000003730A1 (en) * 1998-07-16 2000-01-27 Cheil Jedang Corporation Urease based vaccine against helicobacter infection
WO2000045847A1 (en) * 1999-02-05 2000-08-10 Alk-Abelló A/S Novel mucosal delivery system
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2434732T3 (es) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
WO2008055316A1 (en) * 2006-11-10 2008-05-15 Marshall Barry J Methods and devices for the delivery of peptides into the gastric mucosa
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
WO2015063616A2 (en) 2013-11-04 2015-05-07 Uti Limited Partnership Methods and compositions for sustained immunotherapy
EP3291832A4 (en) 2015-05-06 2018-09-12 UTI Limited Partnership Nanoparticle compositions for sustained therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
WO1992019970A1 (en) * 1991-04-26 1992-11-12 Emanuel Calenoff Methods to detect and treat diseases caused by bacterial allergens
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
EP0967279B1 (en) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
AU2003270987A1 (en) 2004-01-22
PL304419A1 (en) 1995-01-09
DK0625053T3 (da) 2002-08-12
DE69331901D1 (de) 2002-06-13
DE69331901T2 (de) 2002-10-31
HU9402261D0 (en) 1994-10-28
SK280619B6 (sk) 2000-05-16
NZ299149A (en) 1997-12-19
EP0625053B1 (en) 2002-05-08
EP1170016A2 (en) 2002-01-09
PT625053E (pt) 2002-09-30
RO114870B1 (ro) 1999-08-30
EP0625053A1 (en) 1994-11-23
OA10087A (en) 1996-12-18
HUT69938A (en) 1995-09-28
KR100287424B1 (ko) 2001-04-16
WO1994009823A1 (en) 1994-05-11
ZA938203B (en) 1994-06-09
CN1094640A (zh) 1994-11-09
RU2125891C1 (ru) 1999-02-10
US5972336A (en) 1999-10-26
ES2176232T3 (es) 2002-12-01
AU5561994A (en) 1994-05-24
NO942490L (no) 1994-08-22
SG70978A1 (en) 2000-03-21
ATE217196T1 (de) 2002-05-15
CN1111429C (zh) 2003-06-18
FI943171L (fi) 1994-09-01
SK79394A3 (en) 1996-09-04
AU678195B2 (en) 1997-05-22
GEP20012429B (en) 2001-05-25
EP1170016A3 (en) 2002-03-06
PL174448B1 (pl) 1998-07-31
JPH07503255A (ja) 1995-04-06
NO942490D0 (no) 1994-07-01
AU678195C (en) 2003-06-12
CZ284416B6 (cs) 1998-11-11
CA2127283A1 (en) 1994-05-11
MX9306841A (es) 1995-01-31
FI112032B (fi) 2003-10-31
IL107474A (en) 1998-09-24
BR9305711A (pt) 1997-02-18
IL107474A0 (en) 1994-02-27
HU219760B (hu) 2001-07-30
NZ258118A (en) 1997-04-24
CZ160994A3 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
FI943171A0 (fi) Ureaasipohjainen rokote Helicobacter-infektiota vastaan
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
IT1237764B (it) Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RU93058676A (ru) Оральное лечение геликобактерной инфекции
NO920350D0 (no) Konjugat av pneumokokkpolysakkarid og immunogent protein,fremgangsmaate for fremstilling av konjugatet, samt vaksine som inneholder konjugatet
FI851859A0 (fi) Antigenpreparat och isolering av saodana preparat.
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
NZ192477A (en) Method for protecting dogs against virulent canine parvovirus using inactivated virus vaccine
ATE244578T1 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
DK0465204T3 (da) Vaccine mod Lyme sygdom
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
EP0636030A4 (en) VACCINE AGAINST THE -I BACTERIAL OXIDE (PASTEURELLIA HAEMOLYTICA).
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
NO934547L (no) Oral behandling av Helicobacter-infeksjon

Legal Events

Date Code Title Description
MA Patent expired